Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| PT PANDA TherapeuticsCompany profile PANDA Therapeutics develops an antibody-based platform targeting protein aggregates involved in Alzheimer’s disease. PANDA Therapeutics develops an antibody-based platform targeting protein aggregates involved in Alzheimer’s disease. | CHF 100K | Venture Kick Stage IIIUndisclosed | Biotech | Switzerland | Investors | |
| A Develops oligonucleotide therapeutics targeting chronic hepatitis B | $120M | Series CSeries C+ | Biotech | United States | Investors | |
| PT ProFound TherapeuticsCompany profile Uses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia Uses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia | $35M | StrategicUndisclosed | Biotech | United States | Investors | |
| T TransfyrCompany profile Physical AI platform capturing real-world lab science into machine-readable data Physical AI platform capturing real-world lab science into machine-readable data | $25M | Seed | Biotech | United States | Investors | |
| RT Revier TherapeuticsCompany profile Revier Therapeutics develops small-molecule medicines targeting class IIa HDAC enzymes for cardiometabolic diseases. Revier Therapeutics develops small-molecule medicines targeting class IIa HDAC enzymes for cardiometabolic diseases. | €6M | Seed | Biotech | Germany | Investors | |
| AB Adaptyv BioCompany profile Adaptyv Bio runs automated laboratory experiments that help protein designers test their sequences and use measured results to improve the next design. Adaptyv Bio runs automated laboratory experiments that help protein designers test their sequences and use measured results to improve the next design. | $40M | Series A | Biotech | Switzerland | Investors | |
| AT Airway TherapeuticsCompany profile Airway Therapeutics develops biologic drug candidates for respiratory, inflammatory and infectious diseases. Airway Therapeutics develops biologic drug candidates for respiratory, inflammatory and infectious diseases. | $24M | Series E-2Series C+ | Biotech | United States | Investors | |
| O OmicsBankCompany profile Connects fragmented hospital data for drug development and healthcare AI research Connects fragmented hospital data for drug development and healthcare AI research | $2.3M | Seed | Biotech, Healthtech | United States | Investors | |
| PT Pixelgen TechnologiesCompany profile High-throughput platform mapping molecular cell architecture at nanoscale resolution High-throughput platform mapping molecular cell architecture at nanoscale resolution | $15.5M | Series B | Biotech | Sweden | Investors | |
| KI KaliVir ImmunotherapeuticsCompany profile Develops oncolytic immunotherapies for patients with advanced solid tumors Develops oncolytic immunotherapies for patients with advanced solid tumors | $14M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →